A prospective study of autoantibodies to Ezrin and pancreatic cancer risk.

Sun Y, Wu J, Cai H, Wang S, Liu Q, Blot WJ, Shu XO, Cai Q
Cancer Causes Control. 2016 27 (6): 831-5

PMID: 27146838 · PMCID: PMC4970458 · DOI:10.1007/s10552-016-0757-y

PURPOSE - No biomarker is available for pancreatic cancer early detection, but a small prospective European study involving 16 cases and 32 controls raised the possibility that anti-Ezrin autoantibodies may be associated with risk of pancreatic cancer. We aimed to validate this finding in a case-control study nested within a prospective study in the USA.

METHODS - Levels of anti-Ezrin autoantibodies were examined using ELISA in pre-diagnostic plasma samples of 73 cases and 145 matched controls. Paired t test and paired signed rank tests were used to determine the difference between two groups, and conditional logistic regression was used to evaluate the association between anti-Ezrin autoantibody levels and risk of developing pancreatic cancer.

RESULTS - No association was found between levels of anti-Ezrin plasma autoantibodies and subsequent risk of developing pancreatic cancer.

CONCLUSION - Anti-Ezrin autoantibodies did not appear to be useful as a plasma biomarker for early detection of pancreatic cancer.

MeSH Terms (15)

Aged Autoantibodies Case-Control Studies Cytoskeletal Proteins Early Detection of Cancer Enzyme-Linked Immunosorbent Assay Female Humans Logistic Models Male Middle Aged Pancreatic Neoplasms Prospective Studies Risk United States

Connections (1)

This publication is referenced by other Labnodes entities: